Browse the evidence

Higher urinary concentrations of specific phthalate metabolites (MBzP, MEP, MEHHP, MEOHP) are positively associated with increased BMI and waist circumference in adult males (20-59 years), suggesting an obesogenic effect of endocrine-disrupting chemicals.

For adult men, minimizing exposure to plastics containing phthalates (e.g., avoiding heating food in plastic containers, reducing use of certain personal care products) may be a supportive strategy for weight management, given the observed association between higher phthalate levels and increased BMI/waist circumference.

Higher urinary concentrations of MEHP (a metabolite of DEHP) are inversely associated with BMI and waist circumference in adolescent and adult females, suggesting a complex, potentially anti-androgenic or metabolic effect distinct from males.

For women, the relationship between phthalate exposure (specifically DEHP metabolites) and weight is complex and potentially inverse, unlike in men. This highlights the importance of considering hormonal context when evaluating environmental health risks.

Circulating soluble DPP4 (sDPP4) acts as an adipokine that contributes to vascular dysfunction and cardiovascular disease risk in obese and diabetic individuals.

In people with obesity and type 2 diabetes, higher levels of a specific form of the DPP4 enzyme found in the blood are linked to an increased risk of heart and blood vessel problems. Managing blood sugar may help mitigate these risks.

DPP4 inhibitors exert effects beyond incretin regulation by interacting with non-incretin substrates such as SDF-1, NPY, PYY, and Substance P, potentially influencing inflammation, angiogenesis, and appetite.

DPP4 inhibitors may have additional benefits beyond lowering blood sugar, potentially affecting inflammation, appetite, and blood vessel health by preserving other important peptides in the body.

Elevated plasma levels of branched-chain amino acids (BCAAs) are associated with an increased risk of insulin resistance and type 2 diabetes, potentially through the persistent activation of mTORC1 and subsequent serine phosphorylation of IRS-1.

If you have insulin resistance or type 2 diabetes, your blood BCAAs might be high, which is linked to worsening insulin sensitivity. While BCAAs are good for muscle building in healthy individuals, chronically high levels in your blood might be a sign of metabolic dysfunction rather than just a supplement effect. Focus on overall metabolic health and protein quality rather than just high-dose BCAA supplementation if you are at risk for diabetes.

BCAA supplementation or high BCAA diets can improve metabolic parameters such as body composition, glucose tolerance, and insulin sensitivity in specific contexts, such as in high-fat diet-fed mice or by stimulating protein synthesis.

BCAAs can have metabolic benefits, such as improving glucose tolerance in high-fat diet scenarios, but this does not mean they are safe for everyone with insulin resistance. The effect depends heavily on the metabolic context. If you are trying to manage insulin resistance, do not assume BCAA supplements are beneficial without considering your overall metabolic health.

Impaired BCAA metabolism, specifically reduced activity of enzymes like BCATm and BCKDC, leads to the accumulation of BCAAs and their toxic intermediates, contributing to insulin resistance and mitochondrial dysfunction.

If you have insulin resistance, your body might not be breaking down BCAAs efficiently, leading to high levels in your blood. This is not necessarily because you are eating too much protein, but because your metabolic enzymes are less active. Focus on improving overall metabolic health rather than just restricting protein.

Routine screening of serum 25(OH)D levels is not recommended for any population (children, adults, pregnant, obese, dark complexion) in the absence of established clinical indications.

Do not get your vitamin D levels tested unless you have a specific medical condition like hypocalcemia. The guideline states that no specific blood level has been proven to prevent disease, so testing will not change your advice: just take the standard recommended dose.

Increased population-level sugar availability is independently associated with higher type 2 diabetes prevalence, regardless of obesity rates, physical activity, or total caloric intake.

At a population level, higher availability of added sugars correlates with higher diabetes rates, independent of how much people weigh or exercise. While this doesn't mean one soda causes diabetes in one person, reducing sugar availability in communities may help lower overall diabetes prevalence.

Dysbiosis in gut microbiota, characterized by harmful microbial activities such as lipopolysaccharide (LPS) supply and toxin production, is directly linked to the development of obesity, metabolic syndrome, and inflammatory bowel disease (IBD).

Prioritize dietary patterns that support a balanced gut microbiome to prevent dysbiosis, which is linked to obesity, IBD, and metabolic disorders. This involves consuming diverse fibers and fermented foods to maintain the balance between beneficial and harmful microbial activities, thereby reducing systemic inflammation and metabolic risk.

Sirtuin activation (via overexpression or activators like resveratrol/STACs) delays cellular senescence and extends organismal lifespan in model organisms, primarily through DNA repair, telomere maintenance, and interaction with longevity pathways like IIS and AMPK.

Focus on lifestyle factors that naturally boost Sirtuin activity, such as calorie restriction and exercise, which increase NAD+ levels and activate AMPK. While supplements like resveratrol are popular, their direct efficacy in humans is unproven and potentially mediated by off-target effects. Prioritize sleep, stress management, and balanced nutrition to support genomic stability.

Myostatin acts as a negative regulator of skeletal muscle mass by inhibiting protein synthesis and promoting degradation; blocking myostatin signaling increases muscle mass in animal models but has failed to show clinical efficacy in elevating muscle strength in human muscular dystrophy trials.

While myostatin is a key regulator of muscle size, simply targeting it (e.g., via drugs or genetic mutation) increases mass but has not reliably improved strength in human clinical trials. Current research suggests targeting myostatin alone is insufficient for treating muscle wasting in humans, and other factors like activin A may play larger roles in primates.

Irisin, a myokine derived from FNDC5, promotes skeletal muscle hypertrophy and attenuates denervation-induced atrophy by activating IL-6 signaling and satellite cell elevation, although its role in human pathology remains under investigation.

Irisin shows promise in animal studies for building muscle and preventing atrophy, but its role in humans is still being defined. Exercise increases the precursor protein (FNDC5) in humans, but whether this translates to higher circulating irisin levels is debated. It is not yet a validated therapeutic target for human muscle gain.

Decorin is a myokine that directly binds to and inactivates myostatin, thereby promoting muscle growth by inhibiting myostatin's anti-myogenic effects and increasing pro-myogenic factors like Mighty and Myod1.

Decorin is a muscle-derived protein that helps build muscle by blocking myostatin, the body's natural muscle growth brake. By inactivating myostatin, decorin allows pro-growth signals to dominate. It is currently being studied as a potential treatment for muscle wasting.

Vitamin D deficiency impairs mitochondrial respiration, increases reactive oxygen species (ROS), and accelerates cellular aging and apoptosis.

If you are vitamin D deficient, correcting this status may help protect mitochondrial function and reduce oxidative stress, which are linked to aging.

Catheter-based renal denervation reduces sympathetic nerve activity and improves glucose metabolism in patients with resistant hypertension, polycystic ovary syndrome, and obstructive sleep apnea.

For patients with resistant hypertension, PCOS, or sleep apnea, renal denervation may improve glucose metabolism and insulin sensitivity by reducing sympathetic nerve activity. This is a procedural option, not a first-line treatment.

Elevated plasma DPP-4 activity is positively correlated with obesity (BMI) and insulin resistance, potentially acting as a local mediator linking adipose tissue inflammation and hepatic insulin resistance to the pathogenesis of Type 2 Diabetes.

Higher levels of the enzyme DPP-4 are found in people with obesity and insulin resistance. This enzyme may contribute to inflammation in fat and liver tissue, worsening insulin resistance. While DPP-4 inhibitors treat diabetes by preserving incretins, the underlying high DPP-4 levels in obesity might also play a role in metabolic dysfunction, though this mechanism is still being fully understood.

Age-related changes in IgG glycosylation, specifically the decrease in galactosylation, promote systemic inflammation (inflammaging), which actively contributes to the deterioration of the aging organism.

This research highlights that inflammation is a key driver of aging, linked to specific changes in your immune system's sugar coatings. While you cannot directly 'take' a glycan supplement, understanding that lifestyle factors (diet, stress, activity) influence these pathways suggests that maintaining a healthy lifestyle may help preserve beneficial glycosylation patterns, potentially slowing inflammatory aging.

2-deoxy-D-glucose (2DG) acts as a calorie restriction mimetic by inhibiting glycolysis, thereby reducing plasma insulin and body temperature without significantly reducing food intake or body weight in rats.

This paper discusses 2-deoxyglucose (2DG) as a potential anti-aging compound in rats that lowers insulin and body temperature without dieting. However, it also notes that high doses are toxic and cause heart failure in rats. There is no human protocol provided, and the compound is not currently a standard human supplement due to safety concerns and lack of long-term human data.

Inhibition of de novo ceramide synthesis (via SPT inhibitors like myriocin or genetic knockdown) reverses insulin resistance and improves glucose tolerance in rodent models of obesity and high-fat feeding.

This research suggests that high levels of ceramides, often resulting from saturated fat intake and obesity, actively block insulin signaling. While this study used drug inhibitors in mice, it implies that reducing saturated fat intake or managing lipid metabolism might be crucial for improving insulin sensitivity in humans, beyond just calorie counting.

Saturated fatty acids induce insulin resistance by activating TLR4, which drives the transcriptional upregulation of enzymes for de novo ceramide synthesis.

Saturated fats may trigger an inflammatory response (TLR4) that increases ceramide levels, blocking insulin. This suggests that the type of fat matters more than just the presence of fat, as unsaturated fats do not appear to trigger this specific pathway.

Adiponectin improves metabolic health by activating ceramidase, which degrades ceramide and promotes the production of sphingosine-1-phosphate (S1P), thereby opposing ceramide's inhibitory effects on insulin signaling.

Adiponectin, a hormone that improves insulin sensitivity, works by breaking down toxic ceramides. Since adiponectin levels are often low in obesity, maintaining a healthy weight and exercising may be the most effective way to support this protective hormonal pathway.

Activation of AMPK in adipose tissue reduces the secretion of pro-inflammatory cytokines (TNFα and IL-6) and may increase the secretion of the insulin-sensitizing hormone adiponectin.

AMPK activation in fat cells helps lower inflammation (TNFα, IL-6) which is linked to insulin resistance. The effect on boosting beneficial hormones like adiponectin is less clear but may occur indirectly.

Cellular senescence and the resulting Senescence-Associated Secretory Phenotype (SASP) are primary drivers of chronic low-grade inflammation (inflammaging) in aging, contributing to age-related diseases such as atherosclerosis, cancer, and diabetes.

Aging is associated with the accumulation of senescent cells that secrete inflammatory signals (SASP), contributing to chronic low-grade inflammation. While lifestyle factors like diet and smoking contribute, they are not the sole drivers; internal biological aging processes play a critical role. Emerging research suggests targeting these senescent cells (senolytics) may be a future strategy to reduce inflammation and improve healthspan.